,,ii  #aagth ,,congress  #b;d ,session  
,s4 #cdhi  ,,in ,,the ,,senate ,,of     
,,the ,,united ,,states  ,january #ab   
7legislative day1 ,january #aj71        
#bjbb,mr4 ,burr 7for himself and ,mr4   
,hickenlooper7 introduced the following 
bill2 which was read twice and referred 
to the ,committee on ,health1           
,education1 ,labor1 and ,pensions  ,a   
,,bill  ,to establish or continue a     
multidisciplinary research program to   
advance the discovery and preclinical   
development of medical products for     
priority virus families and other viral 
pathogens with a significant potential  
to cause a pandemic1 and for other      
purposes4  #a4 ,research centers for    
pathogens of pandemic concern ,subpart  
#f of part ,c of title ,,iv of the      
,public ,health ,service ,act is amended
 by inserting after section #ddg;,c 7#db
 ,u4,s4,c4 #bhe;f-#d7 the following3    
#ddg;,d4 ,research centers for pathogens
 of pandemic concern  7a7 ,in general   
,the ,director of the ,institute1 in    

collaboration1 as appropriate1 with the 
directors of applicable institutes1     
centers1 and divisions of the ,national 
,institutes of ,health1 and the         
,director of the ,biomedical ,advanced  
,research and ,development ,authority1  
shall establish or continue a           
multidisciplinary research program to   
advance the discovery and preclinical   
development of medical products for     
priority virus families and other viral 
pathogens with a significant potential  
to cause a pandemic1 through support for
 research centers4  7b7 ,uses of funds  
,the ,director of the ,institute shall  
award funding through grants1 contracts1
 or cooperative agreements to public or 
private entities1 or consortia of such  
entities1 to provide support for        
research centers described in subsection
 7a7 for the purpose of-- 7#a7          
conducting basic research through       
preclinical development of new medical  
products or technologies1 including     
platform technologies1 to address       

pathogens of pandemic concern2  7#b7    
identifying potential targets for       
therapeutic candidates1 including       
antivirals1 to treat such pathogens2    
7#c7 identifying existing medical       
products with the potential to address  
such pathogens1 including candidates    
that could be used in outpatient        
settings2 and  7#d7 carrying out or     
supporting other research related to    
medical products to address such        
pathogens1 as determined appropriate by 
the ,director4  7c7 ,coordination ,the  
,director of the ,institute shall1 as   
appropriate1 provide for the            
coordination of activities among the    
centers described in subsection 7a71    
including through-- 7#a7 facilitating   
the exchange of information and regular 
communication among the centers1 as     
appropriate2 and  7#b7 requiring the    
periodic preparation and submission to  
the ,director of reports on the         
activities of each center4  7d7         
,priority ,in awarding funding through  

grants1 contracts1 or cooperative       
agreements under subsection 7a71 the    
,director of the ,institute shall1 as   
appropriate1 give priority to applicants
 with existing frameworks and           
partnerships1 as applicable1 to support 
the advancement of such research4  7e7  
,collaboration ,the ,director of the    
,institute shall-- 7#a7 collaborate with
 the heads of other appropriate ,federal
 departments1 agencies1 and offices with
 respect to the identification of       
additional priority virus families and  
other viral pathogens with a significant
 potential to cause a pandemic2 and     
7#b7 collaborate with the ,director of  
the ,biomedical ,advanced ,research and 
,development ,authority with respect to 
the research conducted by centers       
described in subsection 7a71 including1 
as appropriate1 providing any updates on
 the research advancements made by such 
centers1 identifying any advanced       
research and development needs for such 
countermeasures1 consistent with section

 #cai,l7a77#f71 and taking into         
consideration existing manufacturing    
capacity and future capacity needs for  
such medical products or technologies1  
including platform technologies1        
supported by the centers described in   
subsection 7a74  7f7 ,supplement1 not   
supplant ,any support received by a     
center described in subsection 7a7 under
 this section shall be used to          
supplement1 and not supplant1 other     
public or private support for activities
 authorized to be supported4  4  #b4    
,improving medical countermeasure       
research coordination ,section #djb7;b7 
in the ,public ,health ,service ,act    
7#db ,u4,s4,c4 #bhb7;b77 is amended--   
7#a7 in paragraph 7#bd71 by striking and
 at the end2  7#b7 in paragraph 7#be71  
by striking the period and inserting a  
semicolon2 and  7#c7 by inserting after 
paragraph 7#be7 the following3  7#bf7   
shall consult with the ,assistant       
,secretary for ,preparedness and        
,response1 the ,director of the         

,biomedical ,advanced ,research and     
,development ,authority1 the ,director  
of the ,centers for ,disease ,control   
and ,prevention1 and the heads of other 
,federal agencies and offices1 as       
appropriate1 regarding research needs to
 advance medical countermeasures to     
diagnose1 mitigate1 prevent1 or treat   
harm from any biological agent or toxin1
 including emerging infectious diseases1
 chemical1 radiological1 or nuclear     
agent that may cause a public health    
emergency or other research needs       
related to emerging public health       
threats4  4